Hepato-biliary and pancreatic (HPB) malignancies are a leading cause of death worldwide and their incidence is growing over time. Unfortunately, the vast majority of patients with HPB cancers are not amenable to up-front curative treatment at the time of diagnosis because of locally advanced or systemic disease. In addition, even in case of surgically resected patients a not negligible percentage of patients will experience an early recurrence of their cancer. Therefore, new therapeutic multimodal strategies, including neoadjuvant and per-operative therapies are gaining wide acceptance, given their ability to implement the pool of patients amenable to curative treatments and to increase recurrence free and overall survival. Modern multimodal strategies including targeted drug therapy, chemotherapy (both in neoadjuvant and peri-operative setting), radiotherapy, surgery (preferably minimally invasive when feasible), local ablative therapy etc. are indeed essential to achieve optimal results, improve quality of life and prolong survival.
The goal of this Research Topic is to investigate how multiple treatment modalities can be combined and sequenced in the treatment of HPB neoplasms in order to achieve the best oncological outcomes. Furthermore, the role of innovative approaches such as robotic surgery or immunotherapy still remains to be addressed. In this Research Topic, we invite manuscripts focusing on various aspects of multimodal management of hepatic (both primary and metastatic), pancreatic and biliary tract cancers including: original research, comprehensive reviews and meta-analysis on all modalities that play a role in HPB Cancer Treatment and Preclinical Studies with Treatment Implications.
Topics of interest include but are not limited to:
-Combined treatments of HPB tumors
-Novel procedures (including selective internal radiotherapy (SIRT), stereotaxic radiotherapy, etc.)
-Innovative ablative techniques (including MWA, electroporation, electrochemotherapy, etc.)
-Perioperative chemotherapy protocols
-Management of recurrences
-Minimally invasive surgical techniques (laparoscopic - robotic - endoscopic)
-Recent advances in neoadjuvant chemotherapy
-Immunotherapy in HPB tumors
-Conflicting surgical strategies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Hepato-biliary and pancreatic (HPB) malignancies are a leading cause of death worldwide and their incidence is growing over time. Unfortunately, the vast majority of patients with HPB cancers are not amenable to up-front curative treatment at the time of diagnosis because of locally advanced or systemic disease. In addition, even in case of surgically resected patients a not negligible percentage of patients will experience an early recurrence of their cancer. Therefore, new therapeutic multimodal strategies, including neoadjuvant and per-operative therapies are gaining wide acceptance, given their ability to implement the pool of patients amenable to curative treatments and to increase recurrence free and overall survival. Modern multimodal strategies including targeted drug therapy, chemotherapy (both in neoadjuvant and peri-operative setting), radiotherapy, surgery (preferably minimally invasive when feasible), local ablative therapy etc. are indeed essential to achieve optimal results, improve quality of life and prolong survival.
The goal of this Research Topic is to investigate how multiple treatment modalities can be combined and sequenced in the treatment of HPB neoplasms in order to achieve the best oncological outcomes. Furthermore, the role of innovative approaches such as robotic surgery or immunotherapy still remains to be addressed. In this Research Topic, we invite manuscripts focusing on various aspects of multimodal management of hepatic (both primary and metastatic), pancreatic and biliary tract cancers including: original research, comprehensive reviews and meta-analysis on all modalities that play a role in HPB Cancer Treatment and Preclinical Studies with Treatment Implications.
Topics of interest include but are not limited to:
-Combined treatments of HPB tumors
-Novel procedures (including selective internal radiotherapy (SIRT), stereotaxic radiotherapy, etc.)
-Innovative ablative techniques (including MWA, electroporation, electrochemotherapy, etc.)
-Perioperative chemotherapy protocols
-Management of recurrences
-Minimally invasive surgical techniques (laparoscopic - robotic - endoscopic)
-Recent advances in neoadjuvant chemotherapy
-Immunotherapy in HPB tumors
-Conflicting surgical strategies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.